Shots:
- The Korean MFDS has approved Celltrion’s IND to initiate a P-I trial of CT-P59 in patients with COVID-19. The company has initiated the enrollment and is set to evaluate the safety, tolerability, efficacy, PK, and immunogenicity of CT-P59. The company anticipates the completion of study in Q3’20
- The company anticipates the results of P-II & P-III in patients with mild symptoms, the P-III trial in patients with mod. to sev. COVID-19, and the prevention clinical trial, by the end of 2020
- As part of the prevention study, Celltrion will enroll those who are in close contact with COVID-19 patients and those with no symptoms to evaluate the preventative effects of CT-P59
Click here to read full press release/ article | Ref: Celltrion | Image: The Conversation
